Skip to main content
. 2009 Apr 21;17(8):1453–1464. doi: 10.1038/mt.2009.83

Figure 2.

Figure 2

CD19-specific CAR+ T cells demonstrate antigen-specific killing of CD19+ tumor cells. (a) CAR+ T cell cytotoxic activity towards K562 cells that are engineered to express human CD19 (K19) or target antigen negative wild-type K562 cells (K wild type). Following >10 days expansion, CAR+ T cells (Effector cells) were mixed with the K562 cells (Target cells) at the indicated ratios. Results represent the mean percent of target cell lysis as described in materials. Results are representative of three-independent experiments. (b) Cytotoxic activity of T cells expressing either the aCD19-BB-ζ or the aCD19-Δζ control receptor towards primary human ALL target cells using the same method described in (a). Error bars represent the standard error of the mean for three replicates.